PHOTODYNAMIC THERAPY IN PATIENTS WITH HILAR CHOLANGIOCARCINOMA
https://doi.org/10.17709/2409-2231-2019-6-1-7
Abstract
Extrahepatic bile duct cancer is one of those pathologies in which about 70% of patients due to the prevalence of the tumor process can not receive radical treatment, which determines the need for active implementation of methods that allow, while maintaining a satisfactory quality of life of patients, to increase survival rates.
Due to the peculiarities of localization and development of malignant tumors of the extrahepatic bile ducts, as well as the nature of the disease, special importance in the treatment of these patients is given to various methods of external or internal bile removal and on the second stage of treatment can be considered local or systemic methods of exposure.
Currently, as a method of local therapy in patients with unresectable extrahepatic bile duct cancer, various options of radiation therapy, radiofrequency and microwave ablation, photodynamic therapy are used.
This article presents a literature review covering the feasibility, safety and efficacy of photodynamic therapy in patients with Klatskin tumor.
About the Author
L. I. Moskvicheva
P.Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre
Russian Federation
Russian Federation
oncologist of the ultrasound department
3, 2nd Botkinskiy proezd, Moscow, 125284, Russian Federation
References
1. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014 Jun 21;383 (9935):2168–79. DOI: 10.1016/S0140–6736 (13)61903–0
2. Malignant neoplasms in Russia in 2016 (morbidity and mortality). Edited by Kaprin AD, Starinsky VV, Petrova GV. Moscow: P. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federatio; 2018, p. 250. (In Russian).
3. Blechacz В. Cholangiocarcinoma: current knowledge and new developments. Gut Liver. 2017 Jan 15;11 (1):13–26. DOI: 10.5009/gnl15568.
4. Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the portal hepatis: An unusual tumor with distinctive clinical and pathological features. Am J Med. 1965;34:241–56.
5. Valls C, Ruiz S, Martinez L, Leiva D. Radiological diagnosis and staging of hilar cholangiocarcinoma. World J Gastrointest Oncol. 2013 Jul 15;5 (7):115–26. DOI: 10.4251/wjgo.v5.i7.115
6. Megías VMС, de Andrés CI, Ruizdelgad FC. Pathological aspects of so called «hilar cholangiocarcinoma». World J Gastrointest Oncol. 2013 Jul 15;5 (7):159–70. DOI: 10.4251/wjgo.v5.i7.159
7. Serrablo A, Tejedor L. Outcome of surgical resection in Klatskin tumors. World J Gastrointest Oncol. 2013 Jul 15;5 (7):147–58. DOI: 10.4251/wjgo.v5.i7.147
8. Soares KC, Kamel I, Cosgrove DP, Herman JM, Pawlik TM. Hi¬lar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surg Nutr. 2014 Feb;3 (1):18–34. DOI: 10.3978/j.issn.2304–3881.2014.02.05
9. Rerknimitr R, Angsuwatcharakon P, Ratanachu-ek T, Khor CJ, Ponnudurai R, Moon JH, et al. Asia-Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma. J Gastroenterol Hepatol. 2013 Apr;28 (4):593–607. DOI: 10.1111/jgh.12128
10. Robles R, Bueno FS, Ramírez P, Brusadin R, Parrilla P. Liver transplantation for hilar cholangiocarcinoma. World J Gastroenterol. 2013 Dec 28;19 (48):9209–15. DOI: 10.3748/wjg.v19.i48.9209.
11. Chang WH, Kortan P, Haber GB. Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage. Gastrointest Endosc. 1998 May;47 (5):354–62.
12. Kameda R, Ando T, Kobayashi S, Ueno M, Ohkawa S. A retro¬spective study of chemotherapy with cisplatin plus gemcitabine after the failure of gemcitabine monotherapy for biliary tract cancer. Jpn J Clin Oncol. 2013 Jun;43 (6):636–40. DOI: 10.1093/jjco/hyt059
13. Labib PL, Davidson BR, Sharm RA, Pereira SP. Locoregional therapies in cholangiocarcinoma. Hepat Oncol. 2017 Oct;4 (4):99–109. DOI: 10.2217/hep 2017–0014
14. Moole H, Tathireddy H, Dharmapuri S, Moole V, Boddireddy R, Yedama P, et al. Success of photodynamic therapy in palliating patients with nonresectable cholangiocarcinoma: a systematic review and meta-analysis. World J Gastroenterol. 2017 Feb 21;23 (7):1278–1288. DOI: 10.3748/wjg.v23.i7.1278.
15. Liu J, Xue P, Deng J. Therapeutic effect of photodynamic therapy for nonresectable cholangiocarcinoma. Protocol for a meta-analysis and systematic review. Medicine (Baltimore). 2018 Feb;97 (8): e9863. DOI: 10.1097/MD.0000000000009863
16. Lee TY, Cheon YK, Shim CS, Cho YD. Photodynamic therapy prolongs metal stent patency in patients with unresectable hi¬lar cholangiocarcinoma. World J Gastroenterol. 2012 Oct 21;18 (39):5589–94. DOI: 10.3748/wjg.v18.i39.5589
17. Nyman ES, Hynninen PH. Research advances in the use of tetrapyrrolic photosensitizers for photodynamic therapy. J Photochem Photobiol B. 2004 Jan 23;73 (1–2):1–28.
18. Richter JA, Kahaleh M. Photodynamic therapy: Palliation and endoscopic technique in cholangiocarcinoma. World J Gastrointest Endosc. 2010 Nov 16;2 (11):357–61. DOI: 10.4253/wjge.v2.i11.357
19. McCaughan JS Jr, Mertens BF, Cho C, Barabash RD, Payton HW. Photodynamic therapy to treat tumors of the extrahepatic biliary ducts. A case report. Arch Surg. 1991 Jan;126 (1):111–3.
20. Ortner ME, Caca K, Berr F, Liebetruth J, Mansmann U, Huster D, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology. 2003 Nov;125 (5):1355–63.
21. Kahaleh M, Mishra R, Shami VM, Northup PG, Berg CL, Bash¬lor P, et al. Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy. Clin Gastroenterol Hepatol. 2008 Mar;6 (3):290–7. DOI: 10.1016/j.cgh.2007.12.004
22. Cheon YK, Cho YD, Baek SH, Cha SW, Moon JH, Kim YS, et al. Comparison of survival of advanced hilar cholangiocarcinoma af¬ter biliary drainage alone versus photodynamic therapy with external drainage. Korean J Gastroenterol. 2004 Nov;44 (5):280–7.
23. Zoepf T, Jakobs R, Arnold JC, Apel D, Riemann JF. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol. 2005 Nov;100 (11):2426–30. DOI: 10.1111/j.1572–0241.2005.00318.x
24. Lu Y, Liu L, Wu JC, Bie LK, Gong B. Efficacy and safety of photodynamic therapy for unresectable cholangiocarcinoma: A meta-analysis. Clin Res Hepatol Gastroenterol. 2015 Dec;39 (6):718–24. DOI: 10.1016/j.clinre.2014.10.015
25. Wagner A, Kiesslich T, Neureiter D, Friesenbichler P, Puespoek A, Denzer UW, et al. Photodynamic therapy for hilar bile duct cancer: clinical evidence for improved tumoricidal tissue penetration by temoporfin. Photochem Photobiol Sci. 2013 Jun;12 (6):1065–73. DOI: 10.1039/c3pp25425a
26. Cheon YK, Lee TY, Lee SM, Yoon JY, Shim CS. Long-term out-come of photodynamic therapy compared with biliary stent¬ing alone in patients with advanced hilar cholangiocarcinoma. HPB (Oxford). 2012 Mar;14 (3):185–93. DOI: 10.1111/j.1477– 2574.2011.00424.x
27. Matull WR, Dhar DK, Ayaru L, Sandanayake NS, Chapman MH, Dias A, et al. R0 but not R1/R2 resectionis associated with bet¬ter survival than palliative photodynamic therapy in biliary tract cancer. Liver Int. 2011 Jan;31 (1):99–107. DOI: 10.1111/j.1478–3231.2010.02345.x
28. Witzigmann H, Berr F, Ringel U, Caca K, Uhlmann D, Schop¬pmeyer K, et al. Surgical and palliative management and out¬come in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to R1/R2 resection. Ann Surg. 2006 Aug;244 (2):230–9. DOI: 10.1097/01. sla.0000217639.10331.47
29. Höblinger A, Gerhardt T, Gonzalez-Carmona MA, Hüneburg R, Sauerbruch T, Schmitz V. Feasibility and safety of long-term pho¬todynamic therapy (PDT) in the palliative treatment of patients with hilar cholangiocarcinoma. Eur J Med Res. 2011 Sep 12;16 (9):391–5.
30. Gerhardt T, Rings D, Höblinger A, Heller J, Sauerbruch T, Schepke M. Combination of bilateral metal stenting and trans-stent photodynamic therapy for palliative treatment of hilar cholangiocarcinoma. Z Gastroenterol. 2010 Jan;48 (1):28–32. DOI: 10.1055/s 0028–1109983
31. Knüppel M, Kubicka S, Vogel A, Malek NP, Schneider M, Pa¬pendorf F, et al. Combination of conservative and interventional therapy strategies for intra- and extrahepatic cholangiocellular carcinoma: a retrospective survival analysis. Gastroenterol Res Pract. 2012;2012:190708. DOI: 10.1155/2012/190708
32. Park DH, Lee SS, Park SE, Lee JL, Choi JH, Choi HJ, et al. Ran¬domised phase II trial of photodynamic therapy plus oral fluoropyrimidine, S 1, versus photodynamic therapy alone for unresectable hilar cholangiocarcinoma. Eur J Cancer. 2014 May;50 (7):1259–68. DOI: 10.1016/j.ejca.2014.01.008
33. Wentrup R, Winkelmann N, Mitroshkin A, Prager M, Voder¬holzer W, Schachschal G, et al. Photodynamic therapy plus chemotherapy compared with photodynamic therapy alone in hilar nonresectable cholangiocarcinoma. Gut Liver. 2016 May 23;10 (3):470–5. DOI: 10.5009/gnl15175.
Review
For citations:
Moskvicheva L.I. PHOTODYNAMIC THERAPY IN PATIENTS WITH HILAR CHOLANGIOCARCINOMA. Research and Practical Medicine Journal. 2019;6(1):75-82. (In Russ.) https://doi.org/10.17709/2409-2231-2019-6-1-7
Views:
1042
Email this article 